FINWIRES · TerminalLIVE
FINWIRES

Clarity Plans Phase Three Registrational Study of Neuroendocrine Tumor Treatment Candidate; Shares Jump 12%

By

Clarity Pharmaceuticals (ASX:CU6) plans to conduct a registrational phase three trial of the copper-64-SARTATE treatment candidate in neuroendocrine tumors, following an end of phase meeting with the US Food and Drug Administration, according to a Friday Australian bourse filing.

Trial recruitment remains ongoing in the firm's Clarify phase three registrational trial for copper-64-SAR-bisPSMA as a diagnostic agent in patients with prostate cancer prior to undergoing radical prostatectomy. It is a non-randomized, open-label clinical trial in around 383 participants.

The company held a cash position of AU$178.3 million as of June 30, per the filing. It said it holds over 60% of cash reserves in US dollars, adding that the recent appreciation of the Australian dollar resulted in an unrealized exchange loss of AU$5.9 million as of June 30.

Clarity Pharmaceuticals' shares jumped nearly 12% in recent trading on Friday.

Related Articles

Asia

ASE Technology's Q2 Profit Shoots Up as Revenue Rises 27%

ASE Technology's (TPE:3711) attributable profit surged to NT$21.1 billion in the second quarter from NT$7.52 billion a year earlier.Diluted earnings per share rose to NT$4.61 from NT$1.70 a year earlier.Revenue climbed 27% year over year to NT$191.1 billion due to higher semiconductor assembly, testing and electronic manufacturing services sales. On a sequential basis, revenue increased 10%.Gross margin improved to 21% from 20% in the first quarter, while operating margin rose to 11% from 10%, it said.

TPE:3711
Asia

Fitch Affirms Sinochem at A, Stable Outlook

Fitch Ratings affirmed Sinochem International's (SHA:600500) long-term foreign-currency issuer default rating and senior unsecured rating at A-, with a stable outlook, the ratings firm said Thursday.The new ratings reflected the state-owned firm's parent, Sinochem Holdings Corporation, which was rated with "Low" legal, "Medium" strategic, and "High" operational incentives to support Sinochem.The ratings firm decided to withdraw the ratings due to commercial reasons.

SHA:600500
Asia

Cinda Securities H1 Profit Up 7%, Revenue Rises 20%

Cinda Securities (SHA:601059) posted first-half attributable net profit of 1.10 billion yuan, up 7.2% from 1.02 billion yuan the previous year.Earnings per share were unchanged at 0.30 yuan, according to a filing with the Shanghai bourseOperating revenue climbed 20% year over year to 2.44 billion yuan from 2.04 billion yuan.Shares of the brokerage were down 1% in recent trade.

SHA:601059